所有類別 The 3rd TASL-AALSD Joint SymposiumThe 1st TASL-AASLD Joint Symposium: HBV EliminatioHepatocellular carcinomaTASL 2021 HCC Single Topic Conference-symposiumThe 2st TASL-AASLD Joint Symposium認識B肝與治療 The 3rd TASL-AALSD Joint Symposium Viral hepatitis, hepatocarcinogenesis, and lifelong care 影片長度： The 3rd TASL-AALSD Joint Symposium Emerging liver diseases: new virus or immune dysfunction 影片長度： The 3rd TASL-AALSD Joint Symposium Inherited liver diseases in children and young adults- from diagnosis to treatment 影片長度： The 3rd TASL-AALSD Joint Symposium Liver disease involving mothers and children: from HBV transmission to genetic diseases 影片長度： The 3rd TASL-AALSD Joint Symposium Towards elimination of viral hepatitis in Taiwan: our achievements and what else should be done? 影片長度： The 3rd TASL-AALSD Joint Symposium Path to hepatitis elimination: perspective on treatment and new standard of care 影片長度： 認識B肝與治療 認識B肝與治療 影片長度： Hepatocellular carcinoma Hepatocellular carcinoma 影片長度： TASL 2021 HCC Single Topic Conference-symposium How to optimize second-line HCC treatment 影片長度： Yi-Hsiang Huang TASL 2021 HCC Single Topic Conference-symposium TASL 2021 HCC Single Topic Conference-symposium 影片長度： Yi-Hsiang Huang TASL 2021 HCC Single Topic Conference-symposium Hepatitis CAN’T Wait - Strategies to Reach WHO Goals! 影片長度： Yi-Hsiang Huang TASL 2021 HCC Single Topic Conference-symposium Impact of IMbrave150 on theadvanced HCC treatment landscape: How dose it improve patient outcomes? 影片長度： Stephen L. Chan The 2st TASL-AASLD Joint Symposium HCC Debrief from 2020 AASLD The Liver Meeting 影片長度： Denise Harnois The 2st TASL-AASLD Joint Symposium Evolution of treatment in advanced HCC 影片長度： Josep Llovet The 2st TASL-AASLD Joint Symposium Trends of NASH-HCC risk in Taiwan 影片長度： Jee-Fu Huang 1 2 > 到最後 ，前往第 1 2 頁
